Oragenics Reports $9.8 Million Net Loss for Fiscal Year 2025, Focuses on ONP-002 Development

Oragenics Inc., a development-stage biopharmaceutical company, reported a net loss of $9.8 million for the fiscal year ending December 31, 2025, a slight improvement from a loss of $10.6 million in the previous year. The company's accumulated deficit now stands at approximately $226.6 million. Total operating expenses decreased by 11.3% to $9.4 million, primarily due to a significant reduction in research and development costs, which fell by 41.8% to $2.4 million. This decrease was attributed to a focus on advancing the development of ONP-002, a nasal delivery product candidate aimed at treating mild traumatic brain injury (mTBI), while winding down other programs.

In terms of strategic developments, Oragenics completed a public offering in July 2025, raising approximately $15 million through the issuance of Series H Convertible Preferred Stock and warrants. This followed a previous stock sale in February 2025 that generated $2.6 million. The company also issued a $3 million promissory note in March 2025, which was repaid in full by July 2025. As of December 31, 2025, Oragenics had $8.4 million in cash and cash equivalents, which is expected to fund operations through the third quarter of 2026, depending on the timing and scope of development activities.

Oragenics is currently focused on the clinical development of ONP-002, which has completed Phase 1 trials and is expected to enter Phase 2a trials in Q1 2026. The company has made significant progress in its product development timeline, with plans for a U.S.-based Phase 3 trial estimated to start in Q1 2028. The ONP-002 product is designed to be administered via a novel intranasal device, which the company believes will allow for rapid delivery to the brain, potentially addressing a significant unmet medical need in the treatment of concussions.

Despite these advancements, the company faces substantial risks, including the need for additional capital to continue operations and the uncertainty surrounding regulatory approvals. Oragenics has not yet generated any revenue from product sales and has incurred significant operating losses since its inception. The company’s ability to continue as a going concern is contingent upon its ability to secure additional funding, which may include equity or debt financing, strategic collaborations, or licensing agreements. The management has expressed that without sufficient capital, the company may need to delay or reduce its development programs, which could adversely affect its business prospects.